JP2008536807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536807A5 JP2008536807A5 JP2007558143A JP2007558143A JP2008536807A5 JP 2008536807 A5 JP2008536807 A5 JP 2008536807A5 JP 2007558143 A JP2007558143 A JP 2007558143A JP 2007558143 A JP2007558143 A JP 2007558143A JP 2008536807 A5 JP2008536807 A5 JP 2008536807A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- formula
- topical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000017497 prostate disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65739005P | 2005-03-02 | 2005-03-02 | |
| US60/657,390 | 2005-03-02 | ||
| PCT/US2006/007143 WO2006093993A1 (en) | 2005-03-02 | 2006-03-02 | Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196525A Division JP5613206B2 (ja) | 2005-03-02 | 2012-09-06 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008536807A JP2008536807A (ja) | 2008-09-11 |
| JP2008536807A5 true JP2008536807A5 (OSRAM) | 2012-10-25 |
| JP5130453B2 JP5130453B2 (ja) | 2013-01-30 |
Family
ID=36941503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558143A Active JP5130453B2 (ja) | 2005-03-02 | 2006-03-02 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
| JP2012196525A Active JP5613206B2 (ja) | 2005-03-02 | 2012-09-06 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196525A Active JP5613206B2 (ja) | 2005-03-02 | 2012-09-06 | 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875599B2 (OSRAM) |
| EP (2) | EP1853619B1 (OSRAM) |
| JP (2) | JP5130453B2 (OSRAM) |
| KR (1) | KR101380959B1 (OSRAM) |
| CN (2) | CN101155823A (OSRAM) |
| AT (1) | ATE482969T1 (OSRAM) |
| AU (1) | AU2006218711B2 (OSRAM) |
| BR (1) | BRPI0607523A2 (OSRAM) |
| CA (1) | CA2599953C (OSRAM) |
| DE (1) | DE602006017175D1 (OSRAM) |
| DK (2) | DK2206719T3 (OSRAM) |
| EA (1) | EA019560B1 (OSRAM) |
| ES (2) | ES2528055T3 (OSRAM) |
| IL (3) | IL185608A (OSRAM) |
| MX (1) | MX2007010593A (OSRAM) |
| NZ (1) | NZ561571A (OSRAM) |
| PL (2) | PL1853619T3 (OSRAM) |
| PT (2) | PT1853619E (OSRAM) |
| SI (2) | SI1853619T1 (OSRAM) |
| WO (1) | WO2006093993A1 (OSRAM) |
| ZA (1) | ZA200708106B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| PL1853619T3 (pl) | 2005-03-02 | 2011-03-31 | Univ Maryland | 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty |
| CA2726734C (en) | 2007-06-06 | 2014-10-07 | University Of Maryland, Baltimore | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer |
| GB2470873A (en) * | 2008-03-12 | 2010-12-08 | Univ Maryland | Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer |
| US20100048912A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2009120565A2 (en) * | 2008-03-25 | 2009-10-01 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| US8785423B2 (en) * | 2008-04-14 | 2014-07-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases |
| EP2334686B1 (en) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
| JP2012506906A (ja) * | 2008-10-28 | 2012-03-22 | バイオマリン ファーマシューティカル インコーポレイテッド | デカヒドロ−１ｈ−インデノキノリンおよびデカヒドロ−３ｈ−シクロペンタフェナントリジノンｃｙｐ１７インヒビター |
| GB2479693B (en) * | 2009-02-05 | 2014-04-09 | Tokai Pharmaceuticals Inc | Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| GB2514957A (en) * | 2009-02-05 | 2014-12-10 | Tokai Pharmaceuticals Inc | Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent |
| JP5456891B2 (ja) | 2009-06-26 | 2014-04-02 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
| EP2461814A4 (en) | 2009-08-07 | 2012-12-05 | Tokai Pharmaceuticals Inc | PROSTATE CANCER TREATMENT |
| WO2011059969A2 (en) * | 2009-11-13 | 2011-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
| EP2506855A4 (en) * | 2009-11-30 | 2014-07-30 | Harbor Biosciences Inc | ANTICARCINOMA COMPOUNDS AND SCREENING METHODS |
| CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
| JP2013545815A (ja) * | 2010-12-16 | 2013-12-26 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｃｙｐ１１ｂ、ｃｙｐ１７および／またはｃｙｐ２１阻害剤 |
| AU2012249421B9 (en) | 2011-04-28 | 2015-10-22 | Novartis Ag | 17alpha-hydroxylase/C17,20-lyase inhibitors |
| AU2012284053A1 (en) * | 2011-07-18 | 2014-01-23 | Tokai Pharmaceuticals, Inc. | Novel compositions and methods for treating prostate cancer |
| JP2015503508A (ja) * | 2011-12-22 | 2015-02-02 | トーカイ ファーマシューティカルズ，インク． | ＰＩ３Ｋ／ｍＴＯＲ阻害剤を使用する併用療法のための方法および組成物 |
| RU2015137617A (ru) * | 2013-03-14 | 2017-04-18 | Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер | Агенты, подавляющие андрогенные рецепторы, и их применение |
| AU2014247941C1 (en) * | 2013-04-04 | 2019-10-31 | University Of Maryland, Baltimore | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
| KR20160058774A (ko) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| PE20161405A1 (es) | 2013-12-24 | 2017-01-18 | Harvard College | Analogos de cortistatina y sintesis y usos de los mismos |
| CN103694299A (zh) * | 2014-01-13 | 2014-04-02 | 中国药科大学 | 甾体类雄激素受体抑制剂、其制备方法及其医药用途 |
| CN105732759A (zh) * | 2015-01-29 | 2016-07-06 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法 |
| EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10682362B2 (en) | 2015-10-14 | 2020-06-16 | Wayne State University | Treatments and diagnostics for cancers |
| IT201600083406A1 (it) * | 2016-08-08 | 2018-02-08 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| IT201600121375A1 (it) * | 2016-11-30 | 2018-05-30 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| US11390645B2 (en) | 2016-08-08 | 2022-07-19 | Industriale Chimica S.R.L. | Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene |
| WO2019160890A1 (en) * | 2018-02-13 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase degraders and methods of use |
| US20200369715A1 (en) * | 2018-02-13 | 2020-11-26 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase inhibitors and methods of use |
| AU2020393896A1 (en) | 2019-11-26 | 2022-06-23 | Dana-Farber Cancer Institute, Inc. | Potent and selective azaindole inhibitors of CDK8 and CDK19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA27440A (en) | 1887-08-16 | James T. Walsh | Art of making sheet metal cans, for packing meats, fruits, vegetables, etc. | |
| CH621803A5 (OSRAM) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
| US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5994335A (en) * | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
| RU2351357C2 (ru) | 2003-07-29 | 2009-04-10 | ДОМПЕ ФА.Р.МА. С.п.А. | Фармацевтическая композиция, используемая для мобилизации стволовых клеток |
| PL1853619T3 (pl) * | 2005-03-02 | 2011-03-31 | Univ Maryland | 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty |
-
2006
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en active Active
- 2006-03-02 CA CA2599953A patent/CA2599953C/en active Active
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja active Active
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de active Active
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es active Active
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en active Active
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es active Active
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en active Active
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
-
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
-
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
-
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008536807A5 (OSRAM) | ||
| ES2552087T3 (es) | Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos | |
| JP4694127B2 (ja) | Ｚｄ６４７４とタキサンとを含む組み合わせ療法 | |
| CA2482002A1 (en) | Curcumin analogues and uses thereof | |
| EP2868660B1 (en) | Antitumor effect potentiator comprising an imidazooxazine compound | |
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2003525246A (ja) | 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| JP2004517843A5 (OSRAM) | ||
| JP2009506054A5 (OSRAM) | ||
| CN101808636B (zh) | 黑色素瘤的治疗 | |
| EP3741748B1 (en) | Compound and use thereof in medicine | |
| WO2016014390A1 (en) | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer | |
| US20230382850A1 (en) | Substituted bisphenylalkylurea compounds and methods of treating inflammatory conditions | |
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам | |
| TWI615145B (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| EP3641756B1 (en) | Tricyclic compounds as cyp1 inhibitors | |
| KR20170091610A (ko) | 신규 peg 유도체 | |
| JP5324921B2 (ja) | 抗癌剤としてのデメチルペンクロメジン類似体とその使用 | |
| JP2004528343A (ja) | 抗癌薬の製造のためのピリドインドロン誘導体の使用 | |
| JP2007500205A5 (OSRAM) | ||
| ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico | |
| JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| TWI307628B (en) | Use of zd0473 in combination with a non-platinum based anti-cancer agent | |
| JPWO2015152409A1 (ja) | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |